Key clinical point: Market failure is contributing to the rising costs of prescription drugs.
Major finding: If cost trends had not changed after the entry of new TNF inhibitors after 2009, the costs of etanercept, infliximab, and adalimumab in December 2016 would have been 40%-45% lower.
Study details: An interrupted time series analysis of payment data during 2006-2016 with a linear model that calculated the trends in costs that would have been expected if three new anti-TNFs had not entered the market after 2009.
Disclosures: The study was funded in part by the Myers Family Foundation and one author reported funding from the National Heart, Lung, and Blood Institute.
San-Juan-Rodriguez A et al. JAMA Intern Med. 2019 Feb 18. doi: 10.1001/jamainternmed.2018.7656
This Week's Must Reads
Acute Illness and Cannabis Use in Adults, Ann Intern Med; ePub 2019 Mar 26; Monte, et al
Must Reads in Rheumatology
TNF inhibitor prices rose despite increased drug class competition, San-Juan-Rodriguez A et al. JAMA Intern Med. 2019 Feb 18. doi: 10.1001/jamainternmed.2018.7656
List of medications linked to drug-induced lupus expands, Arnaud L et al. Ann Rheum Dis. 2019 Feb 4. doi: 10.1136/annrheumdis-2018-214598
Screening for Osteoporosis to Prevent Fractures, JAMA; ePub 2018 Jun 26; US Preventive Services Task Force
Psychological Interventions & Chronic Pain Reduction, JAMA Intern Med; ePub 2018 May 7; Niknejad, et al
Calcium & Vitamin D for Lower Fracture Incidence, JAMA; 2017 Dec 26; Zhao, Zeng, et al